BAD and central nervous system cancer: Then, considering the KEGG pathways “Glioma” (Figure 5a) and “Proteoglycans in cancer” (Figure 5b), we evaluated how many miRNAs of each group (BAD-SPECIFIC and shared with GOOD) were involved, how many genes of the pathways could be modulated by upregulated or downregulated miRNAs, and the significance of the association.